March 3, 2023

CureLab Receives $3M from Prominent Biotech Investor Dr. John Ballantyne

Ballantyne is the co-founder and former chief scientific officer of Aldevron, a leading manufacturer of plasmids and other biologicals
November 5, 2022

Biotech Internship Opportunity! FDA/USDA liaison

CureLab Oncology and CureLab Veterinary are looking for interns to work with our FDA/USDA team on regulatory activities
September 10, 2022

ESMO 2022: Interim Results for Treatment of Platinum-Resistant Ovarian Cancer with p62 Plasmid DNA Show Statistically Significant Changes in Progression-Free Survival

While the disease has progressed in all patients receiving standard of care, it did not progress in 40% of the patients receiving standard chemotherapy together with the experimental drug, Elenagen — and for half of the patients in the group, Elenagen has increased the time to disease progression by more than 2.5 times
May 3, 2022

CureLab Oncology Secures Patent Protection for P62 Plasmid Therapeutic in South Korea

Patent registration in South Korea opens door to commercial agreements in an enormous market with high economic potential for CureLab
April 22, 2022

University of Camerino Signs Strategic Partnership with CureLab Veterinary to Revolutionize Cancer Treatment for Companion Animals

The university is also renewing its agreement with CureLab Oncology to support its phase II clinical trials